One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans a ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal. But weight loss doesn't ...

Research suggests caffeine can help with weight loss, but a large dose is necessary to create a response. A 2020 review in ...

The company emphasised that it is ready to meet the growing demand for drug-device combinations and biologics, with ...

Health Canada has issued a recall notice for compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy.

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

A Georgia woman who lost 60 pounds taking semaglutide spent nearly $20,000 on a 'mommy makeover' only to pile the weight back ...